Roger Stupp

Summary

Affiliation: Centre Hospitalier Universitaire Vaudois
Country: Switzerland

Publications

  1. ncbi NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality
    Roger Stupp
    Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland
    Eur J Cancer 48:2192-202. 2012
  2. ncbi Neuro-oncology: oligodendroglioma and molecular markers
    Roger Stupp
    Multidisciplinary Oncology Centre and Laboratory of Tumor Biology and Genetics, Department of Neurosurgery, University of Lausanne Hospitals, 1011 Lausanne, Switzerland
    Lancet Neurol 6:10-2. 2007
  3. ncbi Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial
    Roger Stupp
    Department of Medical Oncology, University Hospital of Lausanne, Lausanne, Switzerland
    Lancet Oncol 10:785-93. 2009
  4. ncbi [A practical guide for the management of gliomas]
    Roger Stupp
    Centre Pluridisciplinaire d Oncologie, Centre Hospitalier Universitaire Vaudois CHUV, 46, Rue du Bugnon, CH 1011 Lausanne, Suisse
    Bull Cancer 94:817-22. 2007
  5. ncbi Changing paradigms--an update on the multidisciplinary management of malignant glioma
    Roger Stupp
    Multidisciplinary Oncology Center, University of Lausanne Hospitals, 46 Rue du Bugnon, Lausanne 1011, Switzerland
    Oncologist 11:165-80. 2006
  6. ncbi Chemoradiotherapy in malignant glioma: standard of care and future directions
    Roger Stupp
    Multidisciplinary Oncology Center, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    J Clin Oncol 25:4127-36. 2007
  7. ncbi Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma
    Roger Stupp
    Centre Hospitalier Universitaire Vaudois and University of Lausanne, Rue du Bugnon 46, Lausanne, Switzerland
    J Clin Oncol 28:2712-8. 2010
  8. ncbi 2010: neuro-oncology is moving!
    Roger Stupp
    Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    Curr Opin Neurol 23:553-5. 2010
  9. ncbi Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
    Roger Stupp
    Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    Lancet Oncol 10:459-66. 2009
  10. ncbi Anaplastic astrocytoma in adults
    Roger Stupp
    University Hospital CHUV, Lausanne, Switzerland
    Crit Rev Oncol Hematol 63:72-80. 2007

Detail Information

Publications81

  1. ncbi NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality
    Roger Stupp
    Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland
    Eur J Cancer 48:2192-202. 2012
    ..Tumour Treatment Fields (TTF), a completely new therapeutic modality in cancer treatment, physically interfere with cell division...
  2. ncbi Neuro-oncology: oligodendroglioma and molecular markers
    Roger Stupp
    Multidisciplinary Oncology Centre and Laboratory of Tumor Biology and Genetics, Department of Neurosurgery, University of Lausanne Hospitals, 1011 Lausanne, Switzerland
    Lancet Neurol 6:10-2. 2007
  3. ncbi Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial
    Roger Stupp
    Department of Medical Oncology, University Hospital of Lausanne, Lausanne, Switzerland
    Lancet Oncol 10:785-93. 2009
    ..The aim of this multicentre, phase II trial was to assess the efficacy and toxicity of a neoadjuvant chemotherapy and radiotherapy followed by surgery in patients with technically operable stage IIIB NSCLC...
  4. ncbi [A practical guide for the management of gliomas]
    Roger Stupp
    Centre Pluridisciplinaire d Oncologie, Centre Hospitalier Universitaire Vaudois CHUV, 46, Rue du Bugnon, CH 1011 Lausanne, Suisse
    Bull Cancer 94:817-22. 2007
    ..The therapeutic options presented here are based on evidences from the literature. In the absence of documented evidence, the empirical choices from our local practice are explained and justified...
  5. ncbi Changing paradigms--an update on the multidisciplinary management of malignant glioma
    Roger Stupp
    Multidisciplinary Oncology Center, University of Lausanne Hospitals, 46 Rue du Bugnon, Lausanne 1011, Switzerland
    Oncologist 11:165-80. 2006
    ..This review summarizes recent developments, focusing on the clinical management of patients in daily neuro-oncology practice...
  6. ncbi Chemoradiotherapy in malignant glioma: standard of care and future directions
    Roger Stupp
    Multidisciplinary Oncology Center, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    J Clin Oncol 25:4127-36. 2007
    ....
  7. ncbi Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma
    Roger Stupp
    Centre Hospitalier Universitaire Vaudois and University of Lausanne, Rue du Bugnon 46, Lausanne, Switzerland
    J Clin Oncol 28:2712-8. 2010
    ..This multicenter, phase I/IIa study investigated the efficacy and safety of cilengitide in combination with standard chemoradiotherapy in newly diagnosed glioblastoma...
  8. ncbi 2010: neuro-oncology is moving!
    Roger Stupp
    Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    Curr Opin Neurol 23:553-5. 2010
    ..The role of vascular endothelial growth factor-inhibiting strategies in the management of recurrent glioma remains unclear and controversial...
  9. ncbi Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
    Roger Stupp
    Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    Lancet Oncol 10:459-66. 2009
    ..We report the final results with a median follow-up of more than 5 years...
  10. ncbi Anaplastic astrocytoma in adults
    Roger Stupp
    University Hospital CHUV, Lausanne, Switzerland
    Crit Rev Oncol Hematol 63:72-80. 2007
    ..In recurrent disease, chemotherapy with temozolomide has been proven to be active and well-tolerated in phase II trials, but no comparative phase III trials of other cytotoxic drugs have been conducted...
  11. ncbi Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group
    R Stupp
    Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    Ann Oncol 22:2144-9. 2011
    ..Sagopilone (ZK 219477), a lipophylic and synthetic analog of epothilone B, that crosses the blood-brain barrier has demonstrated preclinical activity in glioma models...
  12. ncbi Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial
    René Olivier Mirimanoff
    Department of Radiation Oncology, University Hospital Lausanne, Lausanne, Switzerland
    J Clin Oncol 24:2563-9. 2006
    ..We evaluated in this trial whether the recursive partitioning analysis (RPA) retains its overall prognostic value and what the benefit of the combined modality is in each RPA class...
  13. ncbi Modulation of angiogenic and inflammatory response in glioblastoma by hypoxia
    Anastasia Murat
    Laboratory of Brain Tumor Biology and Genetics, University Hospital Lausanne CHUV and University of Lausanne, Lausanne, Switzerland
    PLoS ONE 4:e5947. 2009
    ..Our results associate hypoxia-driven tumor response with inflammation in glioblastoma, hence underlining the importance of tumor-host interaction involving the inflammatory compartment...
  14. ncbi Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
    Roger Stupp
    Multidisciplinary Oncology Center, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    N Engl J Med 352:987-96. 2005
    ..In this trial we compared radiotherapy alone with radiotherapy plus temozolomide, given concomitantly with and after radiotherapy, in terms of efficacy and safety...
  15. ncbi MGMT gene silencing and benefit from temozolomide in glioblastoma
    Monika E Hegi
    Laboratory of Tumor Biology and Genetics, Department of Neurosurgery, University Hospital Lausanne, Lausanne, Switzerland
    N Engl J Med 352:997-1003. 2005
    ....
  16. ncbi Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma
    Anastasia Murat
    Laboratory of Tumor Biology and Genetics, Centre Universitaire Romand de Neurochirurgie, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne 1011, Switzerland
    J Clin Oncol 26:3015-24. 2008
    ..Here, we aimed to identify molecular profiles specific for treatment resistance to the current standard of care of concomitant chemoradiotherapy with the alkylating agent temozolomide...
  17. ncbi Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide
    Monika E Hegi
    Laboratory of Tumor Biology and Genetics of the Neurosurgery Departments of the University Hospitals, Lausanne, Switzerland
    Clin Cancer Res 10:1871-4. 2004
    ..Expression of this excision repair enzyme has been associated with resistance to alkylating chemotherapy...
  18. ncbi Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial
    Monika E Hegi
    Department of Clinical Neurosciences, Lausanne University Hospital, Lausanne, Switzerland
    Acta Neuropathol 123:841-52. 2012
    ..However, the presence of PPN may indicate biological features of clinical relevance for further improvement of therapy...
  19. ncbi New trends in the medical management of glioblastoma multiforme: the role of temozolomide chemotherapy
    Amir R Dehdashti
    Department of Neurosurgery, Multidisciplinary Oncology Center, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    Neurosurg Focus 20:E6. 2006
    ..In this short review the authors summarize the current role of TMZ chemotherapy in the management of GBM, with an emphasis on approved indications and practical aspects...
  20. ncbi Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity
    Monika E Hegi
    Laboratory of Tumor Biology and Genetics, Department of Neurosurgery BH 19 110, Centre Hospitalier Universitaire Vaudois and University of Lausanne, CH 1011 Lausanne, Switzerland
    J Clin Oncol 26:4189-99. 2008
    ..Herein we review the data supporting MGMT as a major mechanism of chemotherapy resistance in malignant gliomas and describe ongoing studies that are testing resistance-modulating strategies...
  21. ncbi Cost of temozolomide therapy and global care for recurrent malignant gliomas followed until death
    Jean Blaise Wasserfallen
    Health Technology Assessment Unit, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Rue du Bugnon, CH 1011 Lausanne, Switzerland
    Neuro Oncol 7:189-95. 2005
    ..We conclude that despite high TMZ drug acquisition costs, care of recurrent malignant gliomas is comparable to other accepted therapies...
  22. ncbi The Wnt inhibitory factor 1 (WIF1) is targeted in glioblastoma and has a tumor suppressing function potentially by induction of senescence
    Wanyu L Lambiv
    Laboratory of Brain Tumor Biology and Genetics, Department of Neurosurgery, Lausanne University Hospital CHUV BH19 110, 46, Rue du Bugnon, Lausanne 1011, Switzerland
    Neuro Oncol 13:736-47. 2011
    ....
  23. ncbi Accelerated postoperative radiotherapy with weekly concomitant boost in patients with locally advanced head and neck cancer
    Abderrahim Zouhair
    Department of Radiation Oncology, Centre Hospitalier Universitaire Vaudois, Bugnon 46, CH-1011 Lausanne, Switzerland
    Radiother Oncol 70:183-8. 2004
    ..Acute and late RT-related morbidity is acceptable. Given the disease progression pattern (distant metastases), adjuvant chemotherapy should be considered...
  24. ncbi Comparison of neoadjuvant cisplatin-based chemotherapy versus radiochemotherapy followed by resection for stage III (N2) NSCLC
    Edgardo Pezzetta
    Department of Thoracic Surgery, Centre Hospitalier Universitaire Vaudois, University of Lausanne, CH-1011 Lausanne, Switzerland
    Eur J Cardiothorac Surg 27:1092-8. 2005
    ....
  25. ncbi Elevated levels of MIC-1/GDF15 in the cerebrospinal fluid of patients are associated with glioblastoma and worse outcome
    Sophie Shnaper
    Department of Neurosurgery, Laboratory of Brain Tumor Biology and Genetics, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    Int J Cancer 125:2624-30. 2009
    ..007, log-rank test). In conclusion, MIC-1/GDF15 protein measured in the CSF may have diagnostic and prognostic value in patients with intracranial tumors...
  26. ncbi Can we afford to add chemotherapy to radiotherapy for glioblastoma multiforme? Cost-identification analysis of concomitant and adjuvant treatment with temozolomide until patient death
    Jean Blaise Wasserfallen
    Health Technology Assessment Unit, University Hospital Center of Vaud, Lausanne, Switzerland
    Cancer 101:2098-105. 2004
    ..Adding temozolomide (TMZ) to standard radiotherapy as a first-line therapy for glioma may increase costs to a disproportionate degree compared with the resulting survival benefits...
  27. ncbi Micropapillary pattern in lung adenocarcinoma: aspect on 18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging
    John O Prior
    Department of Nuclear Medicine, Centre Hospitalier Universitaire Vaudois and University of Lausanne, CH 1011 Lausanne, Switzerland
    Interact Cardiovasc Thorac Surg 10:144-5. 2010
    ..This may have potential future treatment implications, as adjuvant or neoadjuvant chemotherapy may be of relevance, even in the early stages of the disease...
  28. ncbi Monitoring multiple angiogenesis-related molecules in the blood of cancer patients shows a correlation between VEGF-A and MMP-9 levels before treatment and divergent changes after surgical vs. conservative therapy
    Khalil Zaman
    Centre Pluridisciplianire d'Oncologie (CePO, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland
    Int J Cancer 118:755-64. 2006
    ..These results warrant a prospective study to compare the effect of surgical tumor removal vs. chemotherapy on some of these markers and to evaluate their prognostic/predictive value...
  29. ncbi A phase I pharmacokinetic study of hypoxic abdominal stop-flow perfusion with gemcitabine in patients with advanced pancreatic cancer and refractory malignant ascites
    Andrea Kuemmerle
    Division de pharmacologie clinique, Departement de Medecine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    Cancer Chemother Pharmacol 63:331-41. 2009
    ....
  30. ncbi [Role of MGMT and clinical applications in brain tumours]
    Christophe Paus
    Service de Neurochirurgie, Centre hospitalier universitaire vaudois CHUV et Université de Lausanne, Bugnon 46, 1011 Lausanne, Suisse
    Bull Cancer 94:769-73. 2007
    ..This particularity can be tested by methylation specific PCR on resected tumour tissue, best on fresh frozen biopsies, and allows identification of patients more susceptible to respond favourably to the treatment...
  31. ncbi Optimal role of temozolomide in the treatment of malignant gliomas
    Roger Stupp
    Multidisciplinary Oncology Center, University of Lausanne Hospitals, 46 Rue du Bugnon, Lausanne 1011, Switzerland
    Curr Neurol Neurosci Rep 5:198-206. 2005
    ..This review summarizes the current knowledge, highlights approved and nonapproved indications, and describes molecular studies that may allow us to identify the patients most likely to benefit from this treatment...
  32. ncbi Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients
    Sandrine Ostermann
    Multidisciplinary Oncology Center, Division of Clinical Pharmacology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    Clin Cancer Res 10:3728-36. 2004
    ..The AUC(CSF)/AUC(plasma) ratio was 20%. Systemic or cerebral exposures are not better predictors than the cumulative dose alone for both efficacy and safety...
  33. ncbi Radiotherapy in low-grade gliomas: Cons
    Rene O Mirimanoff
    Department of Radiation Oncology, University Hospital CHUV, Rue du Bugnon 46, CH 1011, Lausanne, Switzerland
    Semin Oncol 30:34-8. 2003
    ..8 to 2 Gy should be administered using modern, highly conformal techniques. Ideally, RT should be used only within the context of clinical research protocols...
  34. ncbi Listeria brain abscess, Pneumocystis pneumonia and Kaposi's sarcoma after temozolomide
    Vincent Ganière
    University of Lausanne Hospitals, Lausanne, Switzerland
    Nat Clin Pract Oncol 3:339-43; quiz following 343. 2006
    ..This therapy was curtailed after three cycles because of nausea, asthenia, and neuropsychological deterioration. During a subsequent course of radiotherapy, the patient developed fever, headaches, and cutaneous lesions...
  35. ncbi Prognostic factors for low-grade gliomas
    Roger Stupp
    Multidisciplinary Oncology Center, University Hospital (CHUV, 46, Rue du Bugnon, CH-1011 Lausanne, Switzerland
    Semin Oncol 30:23-8. 2003
    ..However, other than surgery, the optimal types and sequence of therapies are not yet established. Improvements in defining prognostic factors will assist in low-grade glioma management...
  36. ncbi Antegrade versus retrograde isolated lung perfusion: doxorubicin uptake and distribution in a sarcoma model
    Thorsten Krueger
    Division of Thoracic Surgery, Multidisciplinary Oncology Center, University Hospital, Lausanne, Switzerland
    Ann Thorac Surg 82:2024-30. 2006
    ..Inasmuch as these tumors derive their vascularization from the bronchial artery system, we hypothesized that retrograde isolated lung perfusion through the pulmonary vein might result in an improved tumor drug uptake...
  37. ncbi Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide
    Roger Stupp
    Department of Medical Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    J Clin Oncol 20:1375-82. 2002
    ..This phase II study was performed to determine the safety, tolerability, and efficacy of concomitant radiation plus temozolomide therapy followed by adjuvant temozolomide therapy in patients with newly diagnosed GBM...
  38. ncbi Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor
    John O Prior
    Nuclear Medicine Department, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland
    J Clin Oncol 27:439-45. 2009
    ....
  39. ncbi Extent and patterns of MGMT promoter methylation in glioblastoma- and respective glioblastoma-derived spheres
    Davide Sciuscio
    Laboratory of Brain Tumor Biology, Department of Clinical Neurosciences, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    Clin Cancer Res 17:255-66. 2011
    ..Epigenetic silencing of the MGMT gene by promoter methylation blunts repair of O6-methyl guanine and has been shown to be a predictive factor for benefit from alkylating agent therapy in glioblastoma...
  40. ncbi Perfusion and diffusion MRI of glioblastoma progression in a four-year prospective temozolomide clinical trial
    Antoine Leimgruber
    Department of Radiology, Lausanne State and University Hospital, Lausanne, Switzerland
    Int J Radiat Oncol Biol Phys 64:869-75. 2006
    ..Specifically, a T1 contrast enhancement over 3 cm in largest diameter together with an increased T2 hypersignal is a marker of inferior prognosis...
  41. ncbi Small cell lung cancer: state of the art and future perspectives
    Roger Stupp
    Multidisciplinary Oncology Center, University Hospital CHUV, 46, Rue du Bugnon, 1011 Lausanne, Switzerland
    Lung Cancer 45:105-17. 2004
    ..Particular emphasis is given to the importance of concomitant and accelerated radiotherapy and consideration of dose-intensive combination chemotherapy regimens...
  42. ncbi The quest for surrogate markers of angiogenesis: a paradigm for translational research in tumor angiogenesis and anti-angiogenesis trials
    Curzio Ruegg
    Centre Pluridisciplinaire d Oncologie, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    Curr Mol Med 3:673-91. 2003
    ..Future anti-angiogenesis trials integrating biological endpoints and surrogate markers or angiogenesis will require close collaboration between clinical investigators and laboratory-based researchers...
  43. ncbi MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status
    Pierre Bady
    Department of Clinical Neurosciences, Lausanne University Hospital, Switzerland
    Acta Neuropathol 124:547-60. 2012
    ....
  44. ncbi Epilepsy in brain tumor patients
    Andrea O Rossetti
    Department of Clinical Neurosciences, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    Curr Opin Neurol 23:603-9. 2010
    ..This review focuses on anticonvulsant treatments in patients with brain tumors and epilepsy, in consideration of the rapidly expanding spectrum of these agents...
  45. ncbi Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes
    Sophie Godard
    Laboratory of Tumor Biology and Genetics, University Hospital (CHUV, 1011 Lausanne, Switzerland
    Cancer Res 63:6613-25. 2003
    ..The separating groups of genes were found by the unsupervised coupled two-way clustering method, and their classification power was validated by a supervised construction of a nearly perfect glioma classifier...
  46. ncbi Correlative studies in neuro-oncology trials: should they influence treatment?
    Monika E Hegi
    Laboratory of Tumor Biology and Genetics, Department of Neurosurgery, University Hospital Lausanne Chuv, 1011 Lausanne, Switzerland
    Curr Oncol Rep 8:54-7. 2006
    ..or move on, incorporate the markers for patient selection or stratification, aim at improving the modestly effective treatments by adding new drugs, and develop alternative therapy strategies for patients selected for their bad predictor?..
  47. ncbi Combined modality treatment with full-dose chemotherapy and concomitant boost radiotherapy for advanced head and neck carcinoma
    Jurg Kutter
    Department of Otorhinolaryngology and Head and Neck Surgery, University Hospital CHUV, Lausanne, Switzerland
    Eur Arch Otorhinolaryngol 262:1-7. 2005
    ..The overall survival of 4 years is promising. Newer regimens causing less acute mucosal and skin toxicity are needed...
  48. ncbi Temozolomide: a milestone in neuro-oncology and beyond?
    Nicole Mutter
    Multidisciplinary Oncology Center University of Lausanne Hospitals 46 Rue du Bugnon, 1011 Lausanne, Switzerland
    Expert Rev Anticancer Ther 6:1187-204. 2006
    ..Temozolomide is under investigation for other disease entities, in particular lower-grade glioma, brain metastases and melanoma...
  49. ncbi Effect of computerisation on the quality and safety of chemotherapy prescription
    Marc Voeffray
    Pharmacy Service, University Hospital, Lausanne, Switzerland
    Qual Saf Health Care 15:418-21. 2006
    ..CONCLUSION: Errors in chemotherapy prescription nearly disappeared after implementation of CPOE. The safety of chemotherapy prescription was markedly improved...
  50. ncbi Epigenetic deregulation of DNA repair and its potential for therapy
    Monika E Hegi
    Laboratory of Brain Tumor Biology and Genetics, University Hospital Lausanne CHUV and University of Lausanne, Lausanne, Switzerland
    Clin Cancer Res 15:5026-31. 2009
    ..quot; Here we review some of the affected repair pathways that, when inactivated, sensitize the tumors to specific drugs and are thus exploitable for individualized therapy...
  51. ncbi Non steroidal anti-inflammatory drugs and COX-2 inhibitors as anti-cancer therapeutics: hypes, hopes and reality
    Curzio Ruegg
    Centre Pluridisciplinaire d Oncologie, University of Lausanne Medical School, CH 1011 Lausanne, Switzerland
    Ann Med 35:476-87. 2003
    ..In this article we will review recent advances in the understanding of the anti-tumor mechanisms of these drugs and discuss their potential application in clinical oncology...
  52. ncbi Cytostatic lung perfusion results in heterogeneous spatial regional blood flow and drug distribution: evaluation of different cytostatic lung perfusion techniques in a porcine model
    Thorsten Krueger
    Department of Thoracic Surgery, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    J Thorac Cardiovasc Surg 132:304-11. 2006
    ..CONCLUSIONS: Cytostatic lung perfusion results in a high overall doxorubicin uptake, which is, however, heterogeneously distributed within the perfused lung...
  53. ncbi Performance of 18F-fluoro-ethyl-tyrosine (18F-FET) PET for the differential diagnosis of primary brain tumor: a systematic review and Metaanalysis
    Vincent Dunet
    Department of Nuclear Medicine, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    J Nucl Med 53:207-14. 2012
    ..The purpose of this systematic review and metaanalysis was to assess the diagnostic performance of (18)F-FET PET in patients with suspicion of PBT...
  54. ncbi Individualized targeted therapy for glioblastoma: fact or fiction?
    Michael Weller
    Department of Neurology, University Hospital Zurich, Zurich, Switzerland
    Cancer J 18:40-4. 2012
    ..Glioblastomas are highly malignant primary brain tumors presumably originating from neuroglial progenitor cells. Median survival is less than 1 year...
  55. ncbi Medulloblastomas in adults: prognostic factors and lessons from paediatrics
    Cristina Nay Fellay
    Department of Oncology, University Hospital Insel, University of Berne, Berne, Switzerland
    Curr Opin Neurol 24:626-32. 2011
    ..This review discusses clinical and new molecular risk factors that will help to optimize treatment in adult medulloblastoma patients...
  56. ncbi Pregabalin in patients with primary brain tumors and seizures: a preliminary observation
    Jan Novy
    Department of Neurology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    Clin Neurol Neurosurg 111:171-3. 2009
    ..Patients with brain tumors and seizures should be treated with non-enzyme-inducing antiepileptic drugs (AED). Some of the newer drugs seem particularly suited in these patients...
  57. ncbi Preoperative hyperfractionated accelerated radiotherapy (HART) and concomitant CPT-11 in locally advanced rectal carcinoma: a phase I study
    Verena Voelter
    Multidisciplinary Oncology Center, University Hospital CHUV, Lausanne, Switzerland
    Int J Radiat Oncol Biol Phys 56:1288-94. 2003
    ..CONCLUSIONS: The recommended Phase II dose of CPT-11 in this setting is 90 mg/m(2)/week. Further Phase II exploration at this dose is warranted...
  58. ncbi T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein
    Julien Laurent
    Division of Experimental Oncology, Multidisciplinary Oncology Center, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    J Transl Med 11:5. 2013
    ....
  59. ncbi Proangiogenic factor PlGF programs CD11b(+) myelomonocytes in breast cancer during differentiation of their hematopoietic progenitors
    Julien Laurent
    Division of Experimental Oncology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Faculty of Biology and Medicine, Lausanne, Switzerland
    Cancer Res 71:3781-91. 2011
    ..These findings impact breast cancer biology, detection, and treatment...
  60. ncbi MGMT methylation status: the advent of stratified therapy in glioblastoma?
    Peter Hau
    Klinikum der Universitat Regensburg, Klinik und Poliklinik für Neurologie am Bezirksklinikum, 93053 Regensburg, Germany
    Dis Markers 23:97-104. 2007
    ....
  61. ncbi Quality assurance of the EORTC 26981/22981; NCIC CE3 intergroup trial on radiotherapy with or without temozolomide for newly-diagnosed glioblastoma multiforme: the individual case review
    Fatma Ataman
    EORTC, Data Center, Radiotherapy Group, 83 Avenue Mounier, 1200 Brussels, Belgium
    Eur J Cancer 40:1724-30. 2004
    ..In multicentre trials with a large of number of investigators from international and national groups, it is essential to confirm the interinstitutional consistency, qualitatively and quantitatively...
  62. ncbi The role of radio- and chemotherapy in glioblastoma
    Roger Stupp
    Onkologie 28:315-7. 2005
  63. ncbi Health-related quality of life in patients with glioblastoma: a randomised controlled trial
    Martin J B Taphoorn
    Medical Centre Haaglanden, The Hague, The Netherlands
    Lancet Oncol 6:937-44. 2005
    ..This paper reports the health-related quality of life (HRQOL) of the patients in this trial...
  64. ncbi Targeting brain-tumor stem cells
    Roger Stupp
    Nat Biotechnol 25:193-4. 2007
  65. ncbi Methylguanine methyltransferase testing in glioblastoma: when and how?
    Roger Stupp
    J Clin Oncol 25:1459-60. 2007
  66. ncbi Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme: a report from the EORTC 26981/22981 NCI-C CE3 Intergroup Study
    Leida M Lamers
    Institute for Medical Technology Assessment bv, Erasmus University Medical Center, Rotterdam, Netherlands
    Cancer 112:1337-44. 2008
    ..The study aimed to compare the cost-effectiveness of concomitant and adjuvant temozolomide (TMZ) for the treatment of newly diagnosed glioblastoma multiforme versus initial radiotherapy alone from a public health care perspective...
  67. ncbi Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms
    Arnab Chakravarti
    Department of Radiation Oncology, Massachusetts General Hospital Harvard Medical School, Boston, 02114, USA
    Clin Cancer Res 12:4738-46. 2006
    ..In this study, we investigated the mechanisms by which temozolomide enhances radiation response in glioblastoma cells...
  68. ncbi Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3
    Thierry Gorlia
    EORTC Data Centre, Brussels, Belgium
    Lancet Oncol 9:29-38. 2008
    ....
  69. ncbi Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: results of a randomised European Organisation for Research and Treatment of Cancer phase III study (EORTC study 26882)
    Jerzy Hildebrand
    Hopital Universitaire Erasme, Brussels, Belgium
    Eur J Cancer 44:1210-6. 2008
    ..The aim of the present study was to test this adjuvant regimen in a larger number of AA patients...
  70. ncbi Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments
    Alba A Brandes
    Department of Medical Oncology, Azienda Unità Sanitaria Locale Bellaria Maggiore Hospital, Bologna, Italy
    Clin Cancer Res 14:957-60. 2008
    ..As with other targeted agents, prospective trials using specific criteria and standardized methods to evaluate tissue biomarkers are required to find predictors of EGFR inhibitors activity in high-grade glioma patients...
  71. ncbi Management of malignant glioma--quo vadis?
    Roger Stupp
    Onkologie 31:300-2. 2008
  72. ncbi Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study
    Eric Raymond
    Service inter hospitalier de cancérologie, Beaujon University Hospital, Clichy
    J Clin Oncol 26:4659-65. 2008
    ..To evaluate the safety and the efficacy of imatinib in recurrent malignant gliomas...
  73. ncbi Recent developments in the use of chemotherapy in brain tumours
    Martin J van den Bent
    Department of Neuro Oncology, Daniel den Hoed Cancer Center Erasmus University Hospital Rotterdam, P O Box 5201, 3008AE Rotterdam, The Netherlands
    Eur J Cancer 42:582-8. 2006
    ..Trials exploring the role of chemotherapy in low-grade glioma are ongoing. No standard chemotherapy is currently available for highly anaplastic glioma failing first-line temozolomide-based therapy...
  74. ncbi Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme
    David A Reardon
    Duke University Medical Center, Neuro Oncology Program and Department of Surgery, Division of Neurosurgery, 047 Baker House, Box 3624, Durham, North Carolina, 27710, USA
    Expert Opin Investig Drugs 17:1225-35. 2008
    ..Integrins, widely expressed in GBM and tumor vasculature, mediate cell survival, migration and angiogenesis. Cilengitide is a potent alphavbeta3 and alphavbeta5 integrin inhibitor...
  75. ncbi Tenascin-W, a new marker of cancer stroma, is elevated in sera of colon and breast cancer patients
    Martin Degen
    Friedrich Miescher Institute for Biomedical Research, Novartis Research Foundation, Basel, Switzerland
    Int J Cancer 122:2454-61. 2008
    ..These results warrant further studies to evaluate the potential value of serum and tissue tenascin-W levels as diagnostic, prognostic or monitoring biomarker in colorectal, breast and possibly other solid cancers...
  76. ncbi Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer
    Markus M Borner
    Institute of Medical Oncology, Inselspital, Switzerland
    J Clin Oncol 20:1759-66. 2002
    ..To determine the efficacy and tolerability of combining oxaliplatin with capecitabine in the treatment of advanced nonpretreated and pretreated colorectal cancer...
  77. ncbi Integrin inhibitors reaching the clinic
    Roger Stupp
    J Clin Oncol 25:1637-8. 2007
  78. ncbi [New systemic therapies in oncology]
    Khalil Zaman
    Fondation du Centre pluridisciplinaire d oncologie, CHUV, 1011 Lausanne
    Rev Med Suisse 1:1361-2, 1364-5. 2005
    ..The following review summarizes current progress with clinical impact observed these last years...
  79. ncbi Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule
    Michele Ghielmini
    Oncology Institute of Southern Switzerland, Ospedale San Giovanni, 6500 Bellinzona, Switzerland
    Blood 103:4416-23. 2004
    ..In patients with FL, the administration of 4 additional doses of rituximab at 8-week intervals significantly improves the EFS...
  80. ncbi Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research
    Arnaud D Roth
    Department of Oncosurgery, Oncosurgery Unit, Geneva University Hospital, Geneva 14, Switzerland
    J Clin Oncol 25:3217-23. 2007
    ....
  81. ncbi Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial
    Daniel C Betticher
    Swiss Group for Clinical Cancer Research, Bern, Switzerland
    J Clin Oncol 21:1752-9. 2003
    ..A multicenter, phase II trial investigated the efficacy and toxicity of neoadjuvant docetaxel-cisplatin in locally advanced non-small-cell lung cancer (NSCLC) and examined prognostic factors for patients not benefiting from surgery...